Most Read Articles
2 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
6 days ago
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Roshini Claire Anthony, 6 days ago

A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).

Venous thromboembolism incidence similar in obese, nonobese patients taking enoxaparin

11 May 2019

No statistically significant difference exists in venous thromboembolism incidence between obese, overweight and nonobese hospitalized patients receiving approved enoxaparin prophylaxis doses, reports a recent study.

A total of 428 patients were included, of which eight (1.9 percent) had venous thromboembolism (three in the nonobese group; two in the overweight group; three in the obese group). There were no statistically significant differences found between the three groups (p=0.81).

Differences were also not statistically significant between overweight (odds ratio [OR], 0.685; 95 percent CI, 0.115–4.095), obese (OR, 0.797; 0.353–1.796), and combined overweight and obese (OR, 0.656; 0.154–2.799) groups compared to patients with normal body weight when incidence of venous thromboembolism was adjusted for age and sex.

This retrospective cohort study compared the incidence of venous thromboembolism between obese and nonobese hospitalized patients who received prophylactic enoxaparin doses and described enoxaparin dosing strategies used in obese patients.

Participants included those who were admitted to Parkview Regional Medical Center, Parkview Hospital or Parkview Orthopedic Hospital between September 2011 and August 2012 and received at least one dose of 30-mg enoxaparin twice daily or 40-mg enoxaparin once daily for venous thromboembolism prophylaxis.

Patients were classified into three groups based on their body mass index (BMI): group 1 (nonobese: BMI <25 kg/m2), group 2 (overweight: BMI ≥25 kg/m2 but <30 kg/m2) and group 3 (obese: BMI ≥30 kg/m2). Venous thromboembolism occurrence within 90 days, considering day 1 of hospitalization as day 1, was the primary endpoint.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
6 days ago
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Roshini Claire Anthony, 6 days ago

A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).